1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1

Not Quite At The Summit But Tremelimumab Hits A High

 
• By Alexandra Shimmings

Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.    

liver
• Source: Shutterstock

AstraZeneca PLC could be looking at a multi-blockbuster opportunity for its immuno-oncology drug Imfinzi in gastrointestinal cancers on the back of full data from two Phase III studies presented this week at the ASCO GI meeting.

The company reported full data from the HIMALAYA study showing that its investigational CTLA-4 inhibitor tremelimumab may have a future...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Lilly’s Orforglipron Makes Strong Showing In Diabetic Obesity Population

 
• By Alaric DeArment

The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.

Regeneron Plans To File Cemdisiran For gMG But Will Face Tough Market

 
• By Jessica Merrill

Head of hematology clinical development Andres Sirulnik talked to Scrip about the positive Phase III results for the siRNA medicine.

Pipeline Watch: Twelve Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Argenx’s Vyvgart Positioned For Broadest Label In Myasthenia Gravis

 
• By Jessica Merrill

The company reported positive Phase III data in individuals with gMG who are ACHr-Ab seronegative, providing an expansion opportunity.

More from R&D

Pipeline Watch: Twelve Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Argenx’s Vyvgart Positioned For Broadest Label In Myasthenia Gravis

 
• By Jessica Merrill

The company reported positive Phase III data in individuals with gMG who are ACHr-Ab seronegative, providing an expansion opportunity.

Pipeline-In-A-Product: A Retrospective On The Development Of Dupixent

 
• By Jessica Merrill, Kevin Grogan, and Edwin Elmhirst

Dupixent’s success across eight indications is a model other drugmakers would like to replicate. R&D leaders at Sanofi and Regeneron reflect back on the development strategy that built the $15bn product.